Discontinued — last reported Q3 '21
Products & Services · Gross Profit Excluding Other Revenue
Tyvaso — Gross Profit Excluding Other Revenue
United Therapeutics Tyvaso — Gross Profit Excluding Other Revenue increased by 8.5% to $156.40M in Q3 2021 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ1 2017
Last reportedQ3 2021
How to read this metric
A steady or growing trend indicates a healthy, sustainable core business, whereas reliance on other revenue sources may mask underlying product performance issues.
Detailed definition
This metric isolates the core profitability of the product by excluding non-recurring or ancillary revenue streams such...
Peer comparison
Comparable to core product gross margin metrics used by peers to strip out non-operating income.
Metric ID:
uthr_segment_tyvaso_gross_profit_excluding_other_revenueHistorical Data
2 periods
| Q2 '21 | Q3 '21 | |
|---|---|---|
| Value | $144.10M | $156.40M |
| QoQ Change | — | +8.5% |
Range$144.10M – $156.40M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's tyvaso — gross profit excluding other revenue?
- United Therapeutics (UTHR) reported tyvaso — gross profit excluding other revenue of $156.40M in Q3 2021.
- What does tyvaso — gross profit excluding other revenue mean?
- The profit generated strictly from the sale of the product, excluding any secondary or non-core revenue sources.